Priority Lists
Protocol Posting of
Activations
Initial Activation - Effective Date 8/18/2026
MOZART MZL: A Randomized Phase II Study with a Common Control Arm of Mosunetuzumab Monotherapy Evaluated Against Two Experimental Treatment Arms of Either Combination Mosunetuzumab and Zanubrutinib or Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma
| Action Codes | FBR |
| Study Coordinator(s) | Boyu Hu, M.D. |
| Participants | ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS |
Initial Activation - Effective Date 8/18/20226
Randomized Phase III trial of multimodality therapy versus standard of care systemic therapy in HER2 positive (HER2+) de novo (AJCC stage IV) oligometastatic breast cancer with response to initial chemotherapy
| Action Codes | FBR, NR |
Closures
Temporary Closure - Effective Date 8/24/2026
A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma
| Action Codes | NR |
| Study Coordinator(s) | Paul Swiecicki, M.D, |
| Participants | ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS |
Amendments, Revisions, Memoranda
Memorandum - Updated Master Forms Set
A Randomized Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML: A myeloMATCH Substudy
| Action Codes | NR |
| Study Coordinator(s) | Eric Huselton, M.D., Uma Borate, M.D. |
| Participants | ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS, ALL NCI Community Oncology Research Program (NCORP) Affiliates and Subaffiliates |
Memorandum - Updated Master Forms Set
A Randomized Phase II Study Comparing Cytarabine +Daunurubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; A myeloMATCH Clinical Trial
| Action Codes | NR |
Memorandum - IND Withdrawal for 77840: veliparib
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer (TNBC) and/or BRCA Mutation-Associated Breast Cancer, with or without Brain Metastases
| Action Codes | NR |
| Study Coordinator(s) | Eve Rodler, M.D., Priyanka Sharma, M.D., Julie R. Gralow, M.D. |
| Participants | CTSU |
Memorandum - IND Withdrawal of Veliparib – Gastrointestinal Cancers IND #129716
Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC- 737664) in Metastatic Pancreatic Cancer
| Action Codes | NR |
| Study Coordinator(s) | E. Gabriela Chiorean, M.D. |
| Participants | ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS |
Memorandum - IND Safety Report(s) for Daratumumab
Phase III Study of Daratumumab (NSC- 791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
| Action Codes | NR |
| Study Coordinator(s) | Jens Rueter, M.D., Meghna Trivedi, M.D., Douglas Reding, M.D., Banu Symington, MD |
Memorandum - IND Safety Report(s) for Sotorasib (AMG 510)
A PHASE II STUDY OF AMG 510 IN PATIENTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (ECOG-ACRIN LUNG-MAP SUB-STUDY)
| Action Codes | NR |
| Study Coordinator(s) | Sukhmani K. Padda, M.D., David Gerber, M.D. |
Memorandum - Clinical Trial Summary: Patient-Friendly Summary and Social Media Toolkit
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
| Action Codes | ER |
| Study Coordinator(s) | Jennifer Amengual, M.D. |
| Participants | ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS |
Memorandum - IND Safety Report(s) for Daratumumab
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance
| Action Codes | NR |
| Study Coordinator(s) | Sikander Ailawadhi, M.D., Jing Christine Ye, M.D., MSc, Brea Lipe, MD |
| Participants | ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS |
Memorandum - IND Safety Report(s) for Daratumumab
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance
| Action Codes | NR |
| Study Coordinator(s) | Sikander Ailawadhi, M.D., Jing Christine Ye, M.D., MSc, Brea Lipe, MD |
| Participants | ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS |
Memorandum - IND Safety Report(s) for Daratumumab
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
| Action Codes | NR |
Memorandum - S2414 Site Educational Webinar
INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
| Action Codes | NR |
| Study Coordinator(s) | Jeremy Cetnar, M.D., Taofeek K. Owonikoko, M.D., Ph.D |
Memorandum 1 of 2 - Updated Master Forms Set
Phase II/III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)
| Action Codes | NR |
| Study Coordinator(s) | Pedro Barata, M.D., Ulka N. Vaishampayan, M.D., Sumanta K. Pal, M.D., David J. McConkey, Ph.D. |
| Participants | ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS |
Memorandum 2 of 2 - S2419 Site Initiation Training and Intake Calendar Notification
Phase II/III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)
| Action Codes | NR |
| Study Coordinator(s) | Pedro Barata, M.D., Ulka N. Vaishampayan, M.D., Sumanta K. Pal, M.D., David J. McConkey, Ph.D. |
| Participants | ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS |
Memorandum 1 of 2 - S2511 PSR Clarification
Randomized Phase III trial of multimodality therapy versus standard of care systemic therapy in HER2 positive (HER2+) de novo (AJCC stage IV) oligometastatic breast cancer with response to initial chemotherapy
| Action Codes | FBR, NR |
Memorandum 2 of 2 - S2511 Updated Master Forms Set
Randomized Phase III trial of multimodality therapy versus standard of care systemic therapy in HER2 positive (HER2+) de novo (AJCC stage IV) oligometastatic breast cancer with response to initial chemotherapy
| Action Codes | FBR, NR |
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required